← Browse by Condition
Medical Condition

colon adenocarcinoma

Total Trials
2
Recruiting Now
2
Trial Phases
Phase 2

ClinicalMetric tracks all active clinical trials for colon adenocarcinoma sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — colon adenocarcinoma Clinical Trials

How many clinical trials are currently recruiting for colon adenocarcinoma?
ClinicalMetric currently tracks 2 actively recruiting clinical trials for colon adenocarcinoma, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 2. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for colon adenocarcinoma?
colon adenocarcinoma research spans Phase 2 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a colon adenocarcinoma clinical trial?
Eligibility criteria for colon adenocarcinoma trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 2
1
Top Sponsors
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University 1 trial
Alliance for Clinical Trials in Oncology 1 trial

Recruiting Clinical Trials

NCT07468630 Phase 2
Recruiting
Tolecizumab Plus Chemoimmunotherapy for pMMR/MSS Locally Advanced Colon Adenocarcinoma
Enrollment
106 pts
Location
China
Sponsor
Daping Hospital and the Resear...
View Trial →
NCT07143487
Recruiting
Family Communications After Genetic Testing
Enrollment
4,186 pts
Location
United States
Sponsor
Alliance for Clinical Trials i...
View Trial →

Related Conditions

colorectal adenocarcinoma (1) rectal adenocarcinoma (1) stage i colon cancer ajcc v8 (1) stage i colorectal cancer ajcc v8 (1) stage i rectal cancer ajcc v8 (1) stage ii colon cancer ajcc v8 (1) stage ii colorectal cancer ajcc v8 (1) stage ii rectal cancer ajcc v8 (1) stage iii colon cancer ajcc v8 (1) stage iii colorectal cancer ajcc v8 (1) stage iii rectal cancer ajcc v8 (1) stage iv colon cancer ajcc v8 (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology